Tildrakizumab for treating moderate to severe plaque psoriasis

  • Technology appraisal guidance
  • TA575
  • Published: 
Download guidance (PDF)

5 Recommendations for research

5.1 The committee noted that the costs of best supportive care are derived from a study published in 2010 and that clinical practice has changed substantially since then. It therefore considered that it would be valuable to have studies investigating:

  • the costs associated with best supportive care

  • resource use, including frequency and length of hospitalisation, and associated costs.